Biotech · Private company · Princeton, NJ, US

Y-mAbs Therapeutics, Inc.

SEC CIK 0001722964

Track this companyFree. Adds Y-mAbs Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2510 recruiting or active

Pipeline programs18From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline18

131I-omburtamabPhase 3 · NeuroblastomaClinicalTrials.gov · fetched Nov 12, 2026
177Lu-DTPA-omburtamabPhase 2 · Medulloblastoma, ChildhoodClinicalTrials.gov · fetched Nov 12, 2026
Blood drawPhase 2 · NeuroblastomaClinicalTrials.gov · fetched Nov 12, 2026
GM-CSF + NaxitamabPhase 2 · NeuroblastomaClinicalTrials.gov · fetched Nov 12, 2026
Humanized 3F8 Bispecific AntibodyPhase 2 · NeuroblastomaClinicalTrials.gov · fetched Nov 12, 2026
NivatrotamabPhase 2 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
131 I-8H9Phase 1 · Peritoneal CancerClinicalTrials.gov · fetched Nov 12, 2026
CD33*CD3 BsAbPhase 1 · AML, ChildhoodClinicalTrials.gov · fetched Nov 12, 2026
CD38-SADA:177Lu-DOTA ComplexPhase 1 · Non-hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
External Beam RadiotherapyPhase 1 · Brain CancerClinicalTrials.gov · fetched Nov 12, 2026
GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)Phase 1 · SCLCClinicalTrials.gov · fetched Nov 12, 2026
Iodine I 131 MOAB 8H9Phase 1 · Brain and Central Nervous System TumorsClinicalTrials.gov · fetched Nov 12, 2026
Radioactive iodine-labeled monoclonal antibody omburtamabPhase 1 · Brain CancerClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)PHASE1 · RECRUITING · started Jul 2, 2026ClinicalTrials.gov NCT07698899 · fetched Nov 12, 2026
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)PHASE1_PHASE2 · RECRUITING · started Sep 19, 2025ClinicalTrials.gov NCT07011654 · fetched Nov 12, 2026
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaPHASE1 · RECRUITING · started Jun 27, 2025ClinicalTrials.gov NCT07027748 · fetched Nov 12, 2026
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaPHASE1 · TERMINATED · started Apr 21, 2025ClinicalTrials.gov NCT05994157 · fetched Nov 12, 2026
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2PHASE1 · TERMINATED · started Nov 17, 2022ClinicalTrials.gov NCT05130255 · fetched Nov 12, 2026
Naxitamab Added to Induction for Newly Diagnosed High-Risk NeuroblastomaPHASE2 · RECRUITING · started Sep 14, 2022ClinicalTrials.gov NCT05489887 · fetched Nov 12, 2026
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid LeukemiaPHASE1 · TERMINATED · started May 25, 2022ClinicalTrials.gov NCT05077423 · fetched Nov 12, 2026
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory MedulloblastomaPHASE1_PHASE2 · TERMINATED · started Sep 30, 2021ClinicalTrials.gov NCT04167618 · fetched Nov 12, 2026
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung CancerPHASE1_PHASE2 · TERMINATED · started Aug 17, 2021ClinicalTrials.gov NCT04750239 · fetched Nov 12, 2026
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the PeritoneumPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 15, 2019ClinicalTrials.gov NCT04022213 · fetched Nov 12, 2026
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor CancersPHASE1_PHASE2 · TERMINATED · started Feb 22, 2019ClinicalTrials.gov NCT03860207 · fetched Nov 12, 2026
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesPHASE2_PHASE3 · TERMINATED · started Dec 11, 2018ClinicalTrials.gov NCT03275402 · fetched Nov 12, 2026
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 3, 2018ClinicalTrials.gov NCT03363373 · fetched Nov 12, 2026
Study of Chemoimmunotherapy for High-Risk NeuroblastomaEARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Jun 12, 2017ClinicalTrials.gov NCT03189706 · fetched Nov 12, 2026
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk NeuroblastomaPHASE2 · COMPLETED · started Jan 23, 2017ClinicalTrials.gov NCT03033303 · fetched Nov 12, 2026
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaPHASE1 · COMPLETED · started Jan 5, 2016ClinicalTrials.gov NCT02650648 · fetched Nov 12, 2026
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 1, 2015ClinicalTrials.gov NCT02502786 · fetched Nov 12, 2026
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyNA · ACTIVE_NOT_RECRUITING · started Nov 1, 2014ClinicalTrials.gov NCT02307630 · fetched Nov 12, 2026
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 1, 2012ClinicalTrials.gov NCT01757626 · fetched Nov 12, 2026
Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation TherapyPHASE1 · COMPLETED · started Dec 1, 2011ClinicalTrials.gov NCT01502917 · fetched Nov 12, 2026
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive TumorsPHASE1 · COMPLETED · started Aug 15, 2011ClinicalTrials.gov NCT01419834 · fetched Nov 12, 2026
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the PeritoneumPHASE1 · TERMINATED · started Apr 1, 2010ClinicalTrials.gov NCT01099644 · fetched Nov 12, 2026
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaPHASE1_PHASE2 · COMPLETED · started May 27, 2009ClinicalTrials.gov NCT00911560 · fetched Nov 12, 2026
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal CancerPHASE1 · TERMINATED · started Feb 5, 2004ClinicalTrials.gov NCT00089245 · fetched Nov 12, 2026
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young AdultsNO_LONGER_AVAILABLEClinicalTrials.gov NCT05064306 · fetched Nov 12, 2026

SEC filings12

8-K · FORM 8-KSEC EDGAR · filed Sep 16, 2025 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 8, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 8, 2025 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Aug 5, 2025 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jul 15, 2025 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed May 28, 2025 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 13, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 13, 2025 · fetched Nov 12, 2026
10-K/A · 10-K/ASEC EDGAR · filed Apr 29, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 4, 2025 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Mar 4, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 4, 2025 · fetched Nov 12, 2026